Literature DB >> 20304964

The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin.

Karen Block1, Yves Gorin, David D New, Assaad Eid, Tomasz Chelmicki, Amanda Reed, Goutam Ghosh Choudhury, Dipen J Parekh, Hanna E Abboud.   

Abstract

Mutations in the von Hippel-Lindau (VHL) gene give rise to renal cell carcinoma. Reactive oxygen species, generated by Nox oxidases, are involved in tumorigenesis. We have previously demonstrated that in VHL-deficient cells, p22(phox)-dependent Nox1 and Nox4 oxidases maintain hypoxia inducible factor-2alpha (HIF-2alpha) protein expression through an Akt-dependent translational pathway. Phosphorylation of tuberin, by Akt, results in its inactivation. Here we show that diphenyleneiodonium chloride, an inhibitor of Nox oxidases, and small-interfering RNA-mediated down-regulation of p22(phox) inhibit Akt-dependent phosphorylation of tuberin and stabilizes tuberin protein levels in VHL-deficient renal carcinoma cells. p22(phox)-mediated inactivation of tuberin is associated with an increase in ribosomal protein S6 kinase 1 and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1) phosphorylation as well as HIF-2alpha stabilization. Importantly, we find that marked up-regulation of p22(phox) in human renal cell carcinoma correlates with increased tuberin phosphorylation, decreased tuberin protein levels, and increased phosphorylation of 4E-BP1. Our data provide the first evidence that p22(phox)-based Nox oxidases maintain HIF-2alpha protein expression through inactivation of tuberin and downstream activation of ribosomal protein S6 kinase 1/4E-BP1 pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304964      PMCID: PMC2861109          DOI: 10.2353/ajpath.2010.090606

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  38 in total

1.  Dissociation of the eukaryotic initiation factor-4E/4E-BP1 complex involves phosphorylation of 4E-BP1 by an mTOR-associated kinase.

Authors:  K J Heesom; R M Denton
Journal:  FEBS Lett       Date:  1999-09-03       Impact factor: 4.124

2.  Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors.

Authors:  Jaeyul Kwon; Seung-Rock Lee; Kap-Seok Yang; Younghee Ahn; Yeun Ju Kim; Earl R Stadtman; Sue Goo Rhee
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-08       Impact factor: 11.205

3.  Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.

Authors:  Brenda L Petrella; Jouko Lohi; Constance E Brinckerhoff
Journal:  Oncogene       Date:  2005-02-03       Impact factor: 9.867

4.  NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells.

Authors:  Sukhdev S Brar; Zachary Corbin; Thomas P Kennedy; Richelle Hemendinger; Lisa Thornton; Bettina Bommarius; Rebecca S Arnold; A Richard Whorton; Anne B Sturrock; Thomas P Huecksteadt; Mark T Quinn; Kevin Krenitsky; Kristia G Ardie; J David Lambeth; John R Hoidal
Journal:  Am J Physiol Cell Physiol       Date:  2003-04-09       Impact factor: 4.249

5.  The major target of the endogenously generated reactive oxygen species in response to insulin stimulation is phosphatase and tensin homolog and not phosphoinositide-3 kinase (PI-3 kinase) in the PI-3 kinase/Akt pathway.

Authors:  Ji Hae Seo; Younghee Ahn; Seung-Rock Lee; Chang Yeol Yeo; Kyu Chung Hur
Journal:  Mol Biol Cell       Date:  2004-11-10       Impact factor: 4.138

6.  Cell transformation by the superoxide-generating oxidase Mox1.

Authors:  Y A Suh; R S Arnold; B Lassegue; J Shi; X Xu; D Sorescu; A B Chung; K K Griendling; J D Lambeth
Journal:  Nature       Date:  1999-09-02       Impact factor: 49.962

7.  Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase.

Authors:  Rashmi K Ambasta; Pravir Kumar; Kathy K Griendling; Harald H H W Schmidt; Rudi Busse; Ralf P Brandes
Journal:  J Biol Chem       Date:  2004-08-18       Impact factor: 5.157

8.  Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species.

Authors:  Parag Goyal; Norbert Weissmann; Friedrich Grimminger; Cornelia Hegel; Lucius Bader; Frank Rose; Ludger Fink; Hossein A Ghofrani; Ralph T Schermuly; Harald H H W Schmidt; Werner Seeger; Jörg Hänze
Journal:  Free Radic Biol Med       Date:  2004-05-15       Impact factor: 7.376

Review 9.  Rheb fills a GAP between TSC and TOR.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Trends Biochem Sci       Date:  2003-11       Impact factor: 13.807

10.  Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells.

Authors:  Eva C Vaquero; Mouad Edderkaoui; Stephen J Pandol; Ilya Gukovsky; Anna S Gukovskaya
Journal:  J Biol Chem       Date:  2004-05-23       Impact factor: 5.157

View more
  19 in total

1.  Nuclear NADPH oxidase-4 associated with disease progression in renal cell carcinoma.

Authors:  Dharam Kaushik; Keith A Ashcraft; Hanzhang Wang; Karthigayan Shanmugasundaram; Pankil K Shah; Gabriela Gonzalez; Alia Nazarullah; Cooper B Tye; Michael A Liss; Deepak K Pruthi; Ahmed M Mansour; Wasim Chowdhury; Dean Bacich; Hao Zhang; Amanda L Watson; Karen Block; Denise O'Keefe; Ronald Rodriguez
Journal:  Transl Res       Date:  2020-05-31       Impact factor: 7.012

2.  NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2α.

Authors:  Jennifer L Gregg; Robert M Turner; Guimin Chang; Disha Joshi; Ye Zhan; Li Chen; Jodi K Maranchie
Journal:  Cancer Res       Date:  2014-04-22       Impact factor: 12.701

3.  ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer.

Authors:  Xiao Guo; Yin Zhang; Anand Mayakonda; Vikas Madan; Ling-Wen Ding; Le-Hang Lin; Saadiya Zia; Sigal Gery; Jeffrey W Tyner; Wu Zhou; Dong Yin; De-Chen Lin; H Phillip Koeffler
Journal:  Oncogene       Date:  2018-07-06       Impact factor: 9.867

Review 4.  Aiding and abetting roles of NOX oxidases in cellular transformation.

Authors:  Karen Block; Yves Gorin
Journal:  Nat Rev Cancer       Date:  2012-09       Impact factor: 60.716

5.  NADPH-oxidase 4 protects against kidney fibrosis during chronic renal injury.

Authors:  Stellor Nlandu Khodo; Eva Dizin; Gaetan Sossauer; Ildiko Szanto; Pierre-Yves Martin; Eric Feraille; Karl Heinz Krause; Sophie de Seigneux
Journal:  J Am Soc Nephrol       Date:  2012-10-25       Impact factor: 10.121

Review 6.  Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved.

Authors:  Karthigayan Shanmugasundaram; Karen Block
Journal:  Antioxid Redox Signal       Date:  2016-07-27       Impact factor: 8.401

Review 7.  The NOX toolbox: validating the role of NADPH oxidases in physiology and disease.

Authors:  Sebastian Altenhöfer; Pamela W M Kleikers; Kim A Radermacher; Peter Scheurer; J J Rob Hermans; Paul Schiffers; Heidi Ho; Kirstin Wingler; Harald H H W Schmidt
Journal:  Cell Mol Life Sci       Date:  2012-05-31       Impact factor: 9.261

8.  The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.

Authors:  Khanh Vinh Quốc Lu'o'ng; Lan Thi Hoàng Nguyễn
Journal:  Cancer Manag Res       Date:  2012-12-18       Impact factor: 3.989

9.  Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism.

Authors:  Sarah Garrido-Urbani; Stephane Jemelin; Christine Deffert; Stéphanie Carnesecchi; Olivier Basset; Cédric Szyndralewiez; Freddy Heitz; Patrick Page; Xavier Montet; Liliane Michalik; Jack Arbiser; Curzio Rüegg; Karl Heinz Krause; Beat A Imhof; Beat Imhof
Journal:  PLoS One       Date:  2011-02-07       Impact factor: 3.240

10.  Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translation.

Authors:  B K Nayak; D Feliers; S Sudarshan; W E Friedrichs; R T Day; D D New; J P Fitzgerald; A Eid; T Denapoli; D J Parekh; Y Gorin; K Block
Journal:  Oncogene       Date:  2012-08-06       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.